THA
Tharimmune
Stock
Stock
ISIN: US4327053090
Ticker: THAR
US4327053090
THAR
Price
Price
CHART BY
Frequently asked questions
What is Tharimmune's market capitalization?
The market capitalization of Tharimmune is $27.58M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Tharimmune?
Tharimmune's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$6.022. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Tharimmune's stock?
Currently, 1 analysts cover Tharimmune's stock, with a consensus target price of $5.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Tharimmune?
Tharimmune's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$12.11M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Tharimmune?
Tharimmune has a free cash flow of -$9.73M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Tharimmune have, and what sector and industry does it belong to?
Tharimmune employs approximately 2 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Tharimmune's shares?
The free float of Tharimmune is 1.82M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $27.58M
- EPS (TTM)
- -$6.022
- Free Float
- 1.82M
- EBITDA (TTM)
- -$12.11M
- Free Cashflow (TTM)
- -$9.73M
Pricing
- 52W span
- $1.00$9.08
Analyst Ratings
The price target is $5.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
- Employees
- 2
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US4327053090
- Primary Ticker
- THAR
Fundamentals & EOD data from FactSet